
Articles
-
1 week ago |
healio.com | Raj Chovatiya |Erin Michael
In this video, Raj Chovatiya, MD, PhD, discusses findings from the phase 2 STRIDE trial presented at this year’s American Academy of Dermatology Annual Meeting. The study assessed the use of ESK-001 (Alumis), an oral tyrosine kinase 2 inhibitor, among patients with moderate-to-severe plaque psoriasis.
-
1 week ago |
healio.com | Raj Chovatiya |Erin Michael |Carol L. DiBerardino
In this video, Raj Chovatiya, MD, PhD, discusses updates on oral therapies in psoriasis from the American Academy of Dermatology Annual Meeting. “We saw updates largely in the oral therapeutic realm, even more so than the biologic therapeutic realm,” Chovatiya, who is a clinical associate professor for Chicago Medical School at Rosalind Franklin University and assistant clinical professor at George Washington University School of Health Sciences, said.
-
1 month ago |
healio.com | Lawrence F. Eichenfield |Erin Michael |Kristen Dowd
In this exclusive video, Lawrence F. Eichenfield, MD, a member of the Healio Dermatology Peer Perspective Board, discusses psoriasis case reports presented at Maui Derm 2025.
-
1 month ago |
healio.com | Lawrence F. Eichenfield |Erin Michael |Kristen Dowd
In this Healio exclusive video, Lawrence F. Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children’s Hospital-San Diego, discusses areas of unmet need in the field of psoriasis.
-
1 month ago |
healio.com | Lawrence F. Eichenfield |Erin Michael |Kristen Dowd
In this Healio exclusive video, Lawrence F. Eichenfield, MD, discusses oral treatments available to pediatric and adolescent psoriasis discussed at Maui Derm 2025. “From a systemic agent standpoint, we’ve never had an oral agent approved for psoriasis,” Eichenfield, who is chief of pediatric and adolescent dermatology at Rady Children’s Hospital-San Diego and vice chair of the department of dermatology at University of California, San Diego, told Healio.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →